Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomized, double-blind, placebo-controlled, phase 2 trial
Evidence Based Medicine presented by InpharmD™ · InpharmD™
December 10, 20206m 58s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A randomzied, double-blind, placebo-controlled, multicenter, phase 2, pilot trial conducted to determine whether inhaled SNG001 (recombinant interferon beta-1a) has the potential to reduce the severity of lower respiratory tract illness and accelerate recovery in patients diagnosed with COVID-19.